Toll Free: 1-888-928-9744

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Integrated BioTherapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Integrated BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Integrated BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Integrated BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Integrated BioTherapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Integrated BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Integrated BioTherapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Integrated BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Integrated BioTherapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Integrated BioTherapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Integrated BioTherapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Integrated BioTherapeutics, Inc. Snapshot 5
Integrated BioTherapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Integrated BioTherapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Integrated BioTherapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Integrated BioTherapeutics, Inc. - Pipeline Products Glance 11
Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Integrated BioTherapeutics, Inc. - Drug Profiles 14
STEBVax 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AT-62-aa 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Monoclonal Antibody 3 for Staphylococcus Aureus Infections 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
panfilovirus (multivalent) vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SEB-HuMab 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
staphylococcal [serogroup A] (multivalent) vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
staphylococcus aureus (bivalent) vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
staphylococcus aureus (multivalent) vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibodies for Ebola and Marburg Infections 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody 1 for Staphylococcus Aureus Infections 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody 2 for Staphylococcus Aureus Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody 4 for Staphylococcus Aureus Infections 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Integrated BioTherapeutics, Inc. - Pipeline Analysis 30
Integrated BioTherapeutics, Inc. - Pipeline Products by Target 30
Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration 31
Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type 32
Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 33
Integrated BioTherapeutics, Inc. - Recent Pipeline Updates 34
Integrated BioTherapeutics, Inc. - Dormant Projects 35
Integrated BioTherapeutics, Inc. - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Integrated BioTherapeutics, Inc., Key Information 5
Integrated BioTherapeutics, Inc., Key Facts 5
Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2014 8
Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Integrated BioTherapeutics, Inc. - Phase I, 2014 11
Integrated BioTherapeutics, Inc. - Preclinical, 2014 12
Integrated BioTherapeutics, Inc. - Discovery, 2014 13
Integrated BioTherapeutics, Inc. - Pipeline by Target, 2014 30
Integrated BioTherapeutics, Inc. - Pipeline by Route of Administration, 2014 31
Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2014 32
Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 33
Integrated BioTherapeutics, Inc. - Recent Pipeline Updates, 2014 34
Integrated BioTherapeutics, Inc. - Dormant Developmental Projects,2014 35 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify